John A. Double
- Toxicology top 1%
- Molecular Biology top 5%
- Cancer therapeutics and mechanisms 10
- Cancer Research top 5%
- Cancer, Hypoxia, and Metabolism 8
- Pharmaceutical Science top 5%
- Biotechnology top 5%
-
- Synthesis and biological activity 9
-
- Pharmacogenetics and Drug Metabolism 8
- Synthesis of Organic Compounds 6
-
- Cancer Treatment and Pharmacology 7
- Cancer-related Molecular Pathways 6
- Colorectal Cancer Treatments and Studies 6
- Co-authors
- Angelika M. BurgerM C BibbyAnthony P. ReszkaStephen NeidleMichael J. MooreChristoph SchultesFangping DaiRoger M. Phillips
- Journals
- Biochemical Pharmacology (10 papers)British Journal of Cancer (8 papers)European Journal of Cancer (5 papers)
- Partner nations
- United KingdomIrelandNetherlands
In The Last Decade
John A. Double
74 papers receiving 2.4k citations
Peers
Comparison fields: 5 of 110
- Toxicology 163
- Molecular Biology 1.7k
- Cancer Research 358
- Pharmaceutical Science 110
- Biotechnology 135
Countries citing papers authored by John A. Double
This map shows the geographic impact of John A. Double's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John A. Double with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John A. Double more than expected).
Fields of papers citing papers by John A. Double
This network shows the impact of papers produced by John A. Double. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John A. Double. The network helps show where John A. Double may publish in the future.
Co-authorship network
The 25 scholars most cited alongside John A. Double, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2006 | 19 | |
| 2 | 2004 | 76 | |
| 3 | Cytochrome P450 1B1 (CYP1B1) is overexpressed in human colon adenocarcinomas relative to normal colon: implications for drug development. | 2003 | 80 |
| 4 | 2003 | 102 | |
| 5 | 2002 | 7 | |
| 6 | 2002 | 6 | |
| 7 | 2001 | 16 | |
| 8 | 2000 | 65 | |
| 9 | 1998 | 12 | |
| 10 | 1997 | 8 | |
| 11 | 1996 | 140 | |
| 12 | 1995 | 33 | |
| 13 | 1995 | 70 | |
| 14 | 1994 | 16 | |
| 15 | 1993 | 16 | |
| 16 | 1993 | 89 | |
| 17 | 1992 | 48 | |
| 18 | 1989 | 43 | |
| 19 | 1988 | 4 | |
| 20 | 1988 | 5 |
About John A. Double
John A. Double is a scholar working on Toxicology, Oncology and Pharmacology, having authored 75 papers that have together received 2.5k indexed citations. Recurring topics across this work include Cancer therapeutics and mechanisms (10 papers), Synthesis and biological activity (9 papers), Pharmacogenetics and Drug Metabolism (8 papers), Cancer, Hypoxia, and Metabolism (8 papers), Cancer Treatment and Pharmacology (7 papers), Cancer-related Molecular Pathways (6 papers), Colorectal Cancer Treatments and Studies (6 papers) and Synthesis of Organic Compounds (6 papers). The work is most often cited by research in Toxicology (163 citations), Molecular Biology (1.7k citations) and Cancer Research (358 citations). John A. Double has collaborated with scholars based in United Kingdom, Ireland and Netherlands. Frequent co-authors include Angelika M. Burger, M C Bibby, Anthony P. Reszka, Stephen Neidle, Michael J. Moore, Christoph Schultes, Fangping Dai, Roger M. Phillips, Michael C. Bibby and A. M. Burger. Their work appears in journals such as Biochemical Pharmacology, British Journal of Cancer, European Journal of Cancer, Archiv der Pharmazie and JNCI Journal of the National Cancer Institute.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.